

Lajos Pusztai

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2218567/lajos-pusztai-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

344
papers

34,063
citations

79
h-index

181
g-index

370
ext. papers

40,214
ext. citations

8.5
avg, IF

6.84
L-index

#	Paper	IF	Citations
344	Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1275-81	2.2	1917
343	The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. <i>Nature Biotechnology</i> , 2006 , 24, 1151-61	44.5	1691
342	Breast cancer molecular subtypes respond differently to preoperative chemotherapy. <i>Clinical Cancer Research</i> , 2005 , 11, 5678-85	12.9	1415
341	Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. <i>Nature Biotechnology</i> , 2013 , 31, 1023-31	44.5	1353
340	Gene-expression signatures in breast cancer. <i>New England Journal of Medicine</i> , 2009 , 360, 790-800	59.2	1095
339	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet, The</i> , 2012 , 379, 633-40	40	964
338	Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3676-85	2.2	916
337	Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4414-22	2.2	914
336	Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2460-7	2.2	867
335	The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. <i>Oncologist</i> , 2009 , 14, 320-68	5.7	838
334	An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. <i>Cancer Research</i> , 2008 , 68, 6084-91	10.1	806
333	The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. <i>Nature Biotechnology</i> , 2010 , 28, 827-38	44.5	644
332	Pembrolizumab for Early Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 810-821	59.2	599
331	Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. <i>Nature Medicine</i> , 2014 , 20, 1301-9	50.5	596
330	Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4236-44	2.2	556
329	Gene expression profiling in breast cancer: classification, prognostication, and prediction. <i>Lancet, The</i> , 2011 , 378, 1812-23	40	519
328	Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2002 , 20, 1800-8	2.2	473

327	The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. <i>Oncologist</i> , 2003 , 8, 307-25	5.7	462
326	Emergence of constitutively active estrogen receptor- β mutations in pretreated advanced estrogen receptor-positive breast cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 1757-1767	12.9	415
325	A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 305, 1873-81	27.4	414
324	Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. <i>Clinical Cancer Research</i> , 2007 , 13, 228-33	12.9	379
323	Intratumor heterogeneity: seeing the wood for the trees. <i>Science Translational Medicine</i> , 2012 , 4, 127ps10.5	10.5	375
322	Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. <i>New England Journal of Medicine</i> , 2016 , 375, 23-34	59.2	352
321	Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5983-92	2.2	345
320	In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. <i>Clinical Cancer Research</i> , 2014 , 20, 2773-82	12.9	337
319	Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. <i>Annals of Surgical Oncology</i> , 2012 , 19, 1508-16	3.1	329
318	Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 8315-20	11.5	327
317	PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 10208-13	11.5	293
316	Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1049-1060	2.2	288
315	Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. <i>Clinical Cancer Research</i> , 2009 , 15, 441-51	12.9	265
314	Impact of financial burden of cancer on survivors' quality of life. <i>Journal of Oncology Practice</i> , 2014 , 10, 332-8	3.1	245
313	PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Cancer Immunology Research</i> , 2015 , 3, 326-32	12.5	232
312	Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. <i>Cancer</i> , 2005 , 104, 682-91	6.4	232
311	Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. <i>Cytokine</i> , 2004 , 25, 94-102	4	231
310	Targeted therapy in breast cancer: the HER-2/neu gene and protein. <i>Molecular and Cellular Proteomics</i> , 2004 , 3, 379-98	7.6	226

309	Adaptive Randomization of Neratinib in Early Breast Cancer. <i>New England Journal of Medicine</i> , 2016 , 375, 11-22	59.2	223
308	Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. <i>Cancer</i> , 2012 , 118, 2603-14	6.4	220
307	A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer. <i>New England Journal of Medicine</i> , 2015 , 373, 503-10	59.2	219
306	Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 8331-9	2.2	218
305	Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. <i>Breast Cancer Research and Treatment</i> , 2011 , 128, 783-94	4.4	217
304	Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2650-5	2.2	215
303	Commercialized multigene predictors of clinical outcome for breast cancer. <i>Oncologist</i> , 2008 , 13, 477-93	5.7	210
302	Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. <i>JAMA Oncology</i> , 2020 , 6, 676-684	13.4	195
301	A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). <i>Annals of Oncology</i> , 2018 , 29, 1895-1902	10.3	181
300	Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 264-72	9.7	175
299	Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. <i>Journal of Clinical Oncology</i> , 2012 , 30, 729-34	2.2	174
298	Immunotherapy and targeted therapy combinations in metastatic breast cancer. <i>Lancet Oncology</i> , 2019 , 20, e175-e186	21.7	174
297	Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4316-23	2.2	163
296	Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. <i>Lancet Oncology</i> , 2007 , 8, 203-11	21.7	157
295	Estrogen receptors and distinct patterns of breast cancer relapse. <i>Breast Cancer Research and Treatment</i> , 2003 , 78, 105-18	4.4	157
294	Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. <i>Cancer</i> , 2003 , 97, 2960-71	6.4	157
293	Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. <i>Clinical Cancer Research</i> , 2010 , 16, 5351-61	12.9	153
292	Genomic grade index is associated with response to chemotherapy in patients with breast cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3185-91	2.2	153

291	Molecular classification of breast cancer: limitations and potential. <i>Oncologist</i> , 2006 , 11, 868-77	5.7	150
290	Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. <i>Oncologist</i> , 2010 , 15, 1164-8	5.7	133
289	Immunological differences between primary and metastatic breast cancer. <i>Annals of Oncology</i> , 2018 , 29, 2232-2239	10.3	132
288	Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. <i>Oncologist</i> , 2001 , 6, 133-46	5.7	131
287	Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. <i>Clinical Cancer Research</i> , 2003 , 9, 2406-15	12.9	131
286	Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis. <i>Cancer Research</i> , 2009 , 69, 8579-84	10.1	127
285	Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3739-46	2.2	125
284	Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. <i>Cancer</i> , 2015 , 121, 2544-52	6.4	117
283	Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1821-8	2.2	110
282	Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. <i>Annals of Surgery</i> , 2006 , 244, 464-70	7.8	107
281	Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. <i>Cancer Journal (Sudbury, Mass.)</i> , 2003 , 9, 33-41	2.2	104
280	miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2016 , 76, 927-39	10.1	103
279	Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 2061-7	12.9	102
278	Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. <i>Cancer</i> , 2004 , 100, 1814-22	6.4	101
277	Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. <i>Nature Clinical Practice Oncology</i> , 2006 , 3, 621-32		100
276	Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. <i>Lancet Oncology</i> , 2010 , 11, 358-65	21.7	97
275	Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. <i>Cancer</i> , 2004 , 100, 499-506	6.4	97
274	Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the National Cancer Database. <i>Journal of the American College of Surgeons</i> , 2015 , 220, 1063-9	4.4	96

273	Challenges translating breast cancer gene signatures into the clinic. <i>Nature Reviews Clinical Oncology</i> , 2011 , 9, 58-64	19.4	96
272	Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. <i>Breast Cancer Research and Treatment</i> , 2012 , 134, 333-43	4.4	94
271	New Strategies in Breast Cancer: Immunotherapy. <i>Clinical Cancer Research</i> , 2016 , 22, 2105-10	12.9	90
270	Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. <i>Breast Cancer Research and Treatment</i> , 2005 , 89, 149-57	4.4	88
269	Biomarker studies: a call for a comprehensive biomarker study registry. <i>Nature Reviews Clinical Oncology</i> , 2011 , 8, 171-6	19.4	86
268	Effects of tissue handling on RNA integrity and microarray measurements from resected breast cancers. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 1871-83	9.7	84
267	Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2017 , 3, 1707-1711	13.4	81
266	Immune Gene Expression Is Associated with Genomic Aberrations in Breast Cancer. <i>Cancer Research</i> , 2017 , 77, 3317-3324	10.1	80
265	RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial. <i>JAMA Oncology</i> , 2017 , 3, 227-234	13.4	79
264	The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. <i>Clinical Cancer Research</i> , 2005 , 11, 8398-402	12.9	79
263	Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	78
262	HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008 , 108, 183-90	4.4	78
261	Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2003 , 21, 3249-54	2.2	78
260	Primary systemic chemotherapy of invasive lobular carcinoma of the breast. <i>Lancet Oncology</i> , 2007 , 8, 55-62	21.7	77
259	Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. <i>Cancer</i> , 2010 , 116, 5161-7	6.4	76
258	Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2002 , 8, 461-8	2.2	75
257	Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. <i>American Journal of Surgery</i> , 2001 , 182, 601-8	2.7	75
256	Distinct tumor protein p53 mutants in breast cancer subgroups. <i>International Journal of Cancer</i> , 2013 , 132, 1227-31	7.5	74

255	Higher parity and shorter breastfeeding duration: association with triple-negative phenotype of breast cancer. <i>Cancer</i> , 2010 , 116, 4933-43	6.4	74
254	Breast cancer biomarkers and molecular medicine. <i>Expert Review of Molecular Diagnostics</i> , 2003 , 3, 573-858	5.8	74
253	Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. <i>Clinical Cancer Research</i> , 2010 , 16, 711-8	12.9	69
252	Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4287-92	2.2	68
251	High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2013 , 137, 319-27	4.4	67
250	Biomarker analysis of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or Paclitaxel in early-stage breast cancer. <i>Clinical Cancer Research</i> , 2013 , 19, 1587-95	12.9	66
249	Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers. <i>Breast Cancer Research and Treatment</i> , 2014 , 143, 403-9	4.4	64
248	DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes. <i>Oncologist</i> , 2013 , 18, 1063-73	5.7	64
247	The role of tumor initiating cells in drug resistance of breast cancer: Implications for future therapeutic approaches. <i>Drug Resistance Updates</i> , 2010 , 13, 99-108	23.2	64
246	Clinical application of cDNA microarrays in oncology. <i>Oncologist</i> , 2003 , 8, 252-8	5.7	64
245	Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures. <i>PLoS ONE</i> , 2011 , 6, e28403	3.7	63
244	Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX) and the PAM50 breast cancer intrinsic Classifier in early-stage estrogen receptor-positive breast cancer. <i>Oncologist</i> , 2012 , 17, 492-8	5.7	63
243	Targeted therapies for cancer 2004. <i>American Journal of Clinical Pathology</i> , 2004 , 122, 598-609	1.9	61
242	Use of standard markers and incorporation of molecular markers into breast cancer therapy: Consensus recommendations from an International Expert Panel. <i>Cancer</i> , 2011 , 117, 1575-82	6.4	60
241	Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance. <i>Breast Cancer Research</i> , 2017 , 19, 91	8.3	59
240	High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. <i>Clinical Cancer Research</i> , 2015 , 21, 569-76	12.9	58
239	Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ER+ breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 5832-7	11.5	58
238	Reproducibility of research and preclinical validation: problems and solutions. <i>Nature Reviews Clinical Oncology</i> , 2013 , 10, 720-4	19.4	57

237	Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4267-76	2.2	56
236	T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3511-3517	2.2	55
235	Reliability of Whole-Exome Sequencing for Assessing Intratumor Genetic Heterogeneity. <i>Cell Reports</i> , 2018 , 25, 1446-1457	10.6	55
234	The cell cycle regulator 14-3-3 ζ opposes and reverses cancer metabolic reprogramming. <i>Nature Communications</i> , 2015 , 6, 7530	17.4	54
233	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020 , 6, 17	7.8	54
232	Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011 , 125, 785-95	4.4	54
231	Research issues affecting preoperative systemic therapy for operable breast cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 806-13	2.2	54
230	TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase. <i>Cancer Research</i> , 2013 , 73, 6516-25	10.1	53
229	Stability of estrogen receptor status in breast carcinoma: a comparison between primary and metastatic tumors with regard to disease course and intervening systemic therapy. <i>Cancer</i> , 2011 , 117, 705-13	6.4	52
228	CXCR4 expression in early breast cancer and risk of distant recurrence. <i>Oncologist</i> , 2009 , 14, 1182-8	5.7	52
227	Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 6080-6	12.9	52
226	Expression of erbb/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry. <i>Pathology and Oncology Research</i> , 2001 , 7, 171-7	2.6	52
225	Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer. <i>Breast Cancer Research</i> , 2016 , 18, 78	8.3	51
224	Jun activation domain binding protein 1 expression is associated with low p27(Kip1) levels in node-negative breast cancer. <i>Clinical Cancer Research</i> , 2003 , 9, 5652-9	12.9	51
223	Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer. <i>Clinical Cancer Research</i> , 2012 , 18, 1109-19	12.9	50
222	CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers. <i>Breast Cancer Research</i> , 2018 , 20, 154	8.3	50
221	A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients. <i>Genome Medicine</i> , 2015 , 7, 104	14.4	49
220	A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice. <i>Oncologist</i> , 2014 , 19, 453-8	5.7	49

219	TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers. <i>Molecular Oncology</i> , 2014 , 8, 508-19	7.9	49
218	Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. <i>Cancer Research</i> , 2010 , 70, 8852-62	10.1	49
217	Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer. <i>Modern Pathology</i> , 2020 , 33, 1746-1752	9.8	49
216	Standardizing slide-based assays in breast cancer: hormone receptors, HER2, and sentinel lymph nodes. <i>Clinical Cancer Research</i> , 2007 , 13, 2831-5	12.9	48
215	Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy. <i>Cancer</i> , 2005 , 104, 676-81	6.4	48
214	Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis. <i>PLoS Medicine</i> , 2016 , 13, e1002193	11.6	48
213	Structural insights into POT1-TPP1 interaction and POT1 C-terminal mutations in human cancer. <i>Nature Communications</i> , 2017 , 8, 14929	17.4	47
212	Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer. <i>Cancer</i> , 2006 , 107, 1459-66	6.4	46
211	Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 1324-1331	6.1	45
210	Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines. <i>Breast Cancer Research and Treatment</i> , 2010 , 121, 301-9	4.4	45
209	21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.. <i>New England Journal of Medicine</i> , 2021 , 385, 2336-2347	59.2	45
208	Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2636-43	2.2	44
207	CD36-Mediated Metabolic Rewiring of Breast Cancer Cells Promotes Resistance to HER2-Targeted Therapies. <i>Cell Reports</i> , 2019 , 29, 3405-3420.e5	10.6	44
206	Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 1355-1362	13.4	42
205	Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2003 , 21, 3454-61	2.2	41
204	Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 4380-4387	12.9	41
203	Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. <i>Oncologist</i> , 2010 , 15, 246-52	5.7	40
202	Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate. <i>Breast Cancer Research and Treatment</i> , 2010 , 123, 747-55	4.4	40

201	Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers. <i>Clinical Cancer Research</i> , 2011 , 17, 2591-601	12.9	39
200	Current status of prognostic profiling in breast cancer. <i>Oncologist</i> , 2008 , 13, 350-60	5.7	39
199	Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancers. <i>Lancet Oncology</i> , 2019 , 20, e390-e396	21.7	38
198	Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 26-33	12.9	37
197	Comparison of the predictive accuracy of DNA array-based multigene classifiers across cDNA arrays and Affymetrix GeneChips. <i>Journal of Molecular Diagnostics</i> , 2005 , 7, 357-67	5.1	37
196	Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06). <i>Breast Cancer Research and Treatment</i> , 2018 , 168, 631-638	4.4	35
195	Breast cancer biomarkers and molecular medicine: part II. <i>Expert Review of Molecular Diagnostics</i> , 2004 , 4, 169-88	3.8	35
194	Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer. <i>Oncologist</i> , 2016 , 21, 1063-78	5.7	35
193	Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer. <i>Cancer Investigation</i> , 2006 , 24, 187-91	2.1	34
192	Patient preferences regarding incidental genomic findings discovered during tumor profiling. <i>Cancer</i> , 2016 , 122, 1588-97	6.4	34
191	Impact of progression during neoadjuvant chemotherapy on surgical management of breast cancer. <i>Annals of Surgical Oncology</i> , 2011 , 18, 932-8	3.1	32
190	Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 1332-4	9.7	31
189	USP-11 as a predictive and prognostic factor following neoadjuvant therapy in women with breast cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2013 , 19, 10-7	2.2	31
188	First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations. <i>Breast Cancer Research and Treatment</i> , 2011 , 130, 155-64	4.4	31
187	Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	30
186	Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015 , 154, 533-41	4.4	29
185	Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.. <i>New England Journal of Medicine</i> , 2022 , 386, 556-567	59.2	29
184	Unvalidated antibodies and misleading results. <i>Breast Cancer Research and Treatment</i> , 2014 , 147, 457-8	4.4	28

183	Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2017 , 77, 566-578	10.1	28
182	Development of candidate genomic markers to select breast cancer patients for dasatinib therapy. <i>Molecular Cancer Therapeutics</i> , 2010 , 9, 1120-7	6.1	28
181	Expression of BAG-1 and Bcl-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer. <i>Cancer Investigation</i> , 2004 , 22, 248-56	2.1	28
180	Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers 2020 , 8,		27
179	PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 5456-5461	12.9	27
178	Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012 , 135, 619-27	4.4	26
177	Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2011 , 129, 451-8	4.4	26
176	Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4679-83	2.2	26
175	Reproducibility of gene expression signature-based predictions in replicate experiments. <i>Clinical Cancer Research</i> , 2006 , 12, 1721-7	12.9	26
174	Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma. <i>Cancer</i> , 2004 , 101, 258-63	6.4	26
173	A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015 , 152, 95-117	4.4	25
172	Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 1089-1097	9.7	25
171	Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of β -tubulin expression as a predictive marker. <i>Oncologist</i> , 2013 , 18, 787-94	5.7	25
170	Increased epigenetic age in normal breast tissue from luminal breast cancer patients. <i>Clinical Epigenetics</i> , 2018 , 10, 112	7.7	25
169	New generation of molecular prognostic and predictive tests for breast cancer. <i>Seminars in Oncology</i> , 2007 , 34, S10-6	5.5	24
168	Chips to bedside: incorporation of microarray data into clinical practice. <i>Clinical Cancer Research</i> , 2006 , 12, 7209-14	12.9	24
167	Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma. <i>British Journal of Cancer</i> , 2015 , 113, 1003-9	8.7	23
166	Association of LN Evaluation with Survival in Women Aged 70 Years or Older With Clinically Node-Negative Hormone Receptor Positive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2017 , 24, 3073-3081	21	23

165	CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. <i>Breast Cancer Research</i> , 2007 , 9, R87	8.3	23
164	KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS602-TPS602	2.2	23
163	The Influence of Host Factors on the Prognosis of Breast Cancer: Stroma and Immune Cell Components as Cancer Biomarkers. <i>Current Cancer Drug Targets</i> , 2015 , 15, 652-64	2.8	23
162	Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial 2019 , 7, 88		22
161	Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes. <i>Breast Cancer Research and Treatment</i> , 2013 , 137, 407-16	4.4	22
160	Thirty-gene pharmacogenomic test correlates with residual cancer burden after preoperative chemotherapy for breast cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 4078-82	12.9	22
159	Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer. <i>Breast Cancer Research</i> , 2019 , 21, 72	8.3	21
158	Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women. <i>Breast Cancer Research and Treatment</i> , 2019 , 175, 247-259	4.4	21
157	Global gene expression changes induced by prolonged cold ischemic stress and preservation method of breast cancer tissue. <i>Molecular Oncology</i> , 2014 , 8, 717-27	7.9	21
156	Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy. <i>Cancer</i> , 2006 , 106, 42-50	6.4	21
155	Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. <i>International Journal of Cancer</i> , 1999 , 82, 525-31	7.5	21
154	Gene signature-guided dasatinib therapy in metastatic breast cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 5265-71	12.9	20
153	Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy. <i>Oncologist</i> , 2019 , 24, 313-318	5.7	20
152	Predictive and Prognostic Value of the TauProtein in Breast Cancer. <i>Anticancer Research</i> , 2015 , 35, 5179-84	3.4	20
151	Does lymph node status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer?. <i>American Journal of Surgery</i> , 2017 , 214, 1082-1088	2.7	19
150	Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013 , 137, 631-6	4.4	19
149	Statistical measures of transcriptional diversity capture genomic heterogeneity of cancer. <i>BMC Genomics</i> , 2014 , 15, 876	4.5	19
148	Technology insight: Emerging techniques to predict response to preoperative chemotherapy in breast cancer. <i>Nature Clinical Practice Oncology</i> , 2004 , 1, 44-50		19

147	Intratumor Heterogeneity of Homologous Recombination Deficiency in Primary Breast Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 1193-1199	12.9	18
146	Developing safety criteria for introducing new agents into neoadjuvant trials. <i>Clinical Cancer Research</i> , 2013 , 19, 2817-23	12.9	18
145	Germline variant burden in cancer genes correlates with age at diagnosis and somatic mutation burden. <i>Nature Communications</i> , 2020 , 11, 2438	17.4	17
144	Exercise and weight loss interventions and miRNA expression in women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018 , 170, 55-67	4.4	17
143	An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes. <i>British Journal of Cancer</i> , 2018 , 118, 1107-1114	8.7	17
142	Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3484-3492	2.2	17
141	Breast cancer biomarkers. <i>Advances in Clinical Chemistry</i> , 2005 , 40, 99-125	5.8	17
140	Economic Impact of Routine Cavity Margins Versus Standard Partial Mastectomy in Breast Cancer Patients: Results of a Randomized Controlled Trial. <i>Annals of Surgery</i> , 2017 , 265, 39-44	7.8	16
139	Bidirectional Text Messaging to Monitor Endocrine Therapy Adherence and Patient-Reported Outcomes in Breast Cancer. <i>JCO Clinical Cancer Informatics</i> , 2017 , 1, 1-10	5.2	16
138	Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 316-23	4	16
137	Physiologic and pathologic drug resistance in ovarian carcinoma--a hypothesis based on a clonal progression model. <i>Acta Oncologica</i> , 1998 , 37, 629-40	3.2	16
136	Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.. <i>Lancet Oncology, The</i> , 2021 ,	21.7	16
135	Abstract CT011: Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL 2020 ,		16
134	Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. <i>JCO Global Oncology</i> , 2021 , 7, 162-172	3.7	16
133	Effect of CYP2D6 polymorphisms on breast cancer recurrence. <i>Cancer</i> , 2012 , 118, 1221-7	6.4	15
132	Integrated MicroRNA-mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	15
131	Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types. <i>Lancet Oncology, The</i> , 2011 , 12, 1162-8	21.7	15
130	Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2-positive breast cancer using an LC-MALDI-TOF/MS procedure. <i>Proteomics</i> , 2010 , 10, 3525-32	4.8	15

129	Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible?. <i>Drug Resistance Updates</i> , 2004 , 7, 325-31	23.2	15
128	Gene expression profiling of primary breast cancer. <i>Current Oncology Reports</i> , 2005 , 7, 38-44	6.3	15
127	Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. <i>Cancer Cell</i> , 2021 , 39, 989-998.e5	24.3	15
126	Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2200069	2.2	15
125	Randomized controlled trial of weight loss versus usual care on telomere length in women with breast cancer: the lifestyle, exercise, and nutrition (LEAN) study. <i>Breast Cancer Research and Treatment</i> , 2018 , 172, 105-112	4.4	14
124	High-dose chemotherapy: how resistant is breast cancer?. <i>Drug Resistance Updates</i> , 1998 , 1, 62-72	23.2	14
123	The impact of RNA extraction method on accurate RNA sequencing from formalin-fixed paraffin-embedded tissues. <i>BMC Cancer</i> , 2019 , 19, 1189	4.8	14
122	The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer. <i>SpringerPlus</i> , 2015 , 4, 36		13
121	Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue.. <i>JAMA Oncology</i> , 2022 ,	13.4	13
120	Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	12
119	Systematic approach to providing breast cancer survivors with survivorship care plans: a feasibility study. <i>Journal of Oncology Practice</i> , 2015 , 11, e170-6	3.1	12
118	Immunological Differences Between Immune-Rich Estrogen Receptor-Positive and Immune-Rich Triple-Negative Breast Cancers. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	11
117	Reproducibility of Variant Calls in Replicate Next Generation Sequencing Experiments. <i>PLoS ONE</i> , 2015 , 10, e0119230	3.7	11
116	Molecular profiles of invasive mucinous and ductal carcinomas of the breast: a molecular case study. <i>Cancer Genetics and Cytogenetics</i> , 2003 , 141, 148-53		11
115	A systematic evaluation of multi-gene predictors for the pathological response of breast cancer patients to chemotherapy. <i>PLoS ONE</i> , 2012 , 7, e49529	3.7	11
114	Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018 , 169, 333-340	4.4	10
113	Preoperative systemic chemotherapy and pathologic assessment of response. <i>Pathology and Oncology Research</i> , 2008 , 14, 169-71	2.6	10
112	Heterogeneity of breast cancer among patients and implications for patient selection for adjuvant chemotherapy. <i>Pharmaceutical Research</i> , 2006 , 23, 1951-8	4.5	10

111	Mutation based treatment recommendations from next generation sequencing data: a comparison of web tools. <i>Oncotarget</i> , 2016 , 7, 22064-76	3.3	10
110	Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer. <i>Oncologist</i> , 2020 , 25, 943-953	5.7	10
109	Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2021 , 7, 9	7.8	10
108	Defining Risk of Late Recurrence in Early-Stage Estrogen Receptor-Positive Breast Cancer: Clinical Versus Molecular Tools. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1365-1369	2.2	9
107	Standardization efforts enabling next-generation sequencing and microarray based biomarkers for precision medicine. <i>Biomarkers in Medicine</i> , 2015 , 9, 1265-72	2.3	9
106	Identification and Validation of a Novel Biologics Target in Triple Negative Breast Cancer. <i>Scientific Reports</i> , 2019 , 9, 14934	4.9	9
105	Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10 Anniversary Conference. <i>Journal of Cancer</i> , 2017 , 8, 3607-3614	4.5	9
104	The impact of communication style on patient satisfaction. <i>Breast Cancer Research and Treatment</i> , 2019 , 176, 349-356	4.4	8
103	Bone Density Screening in Postmenopausal Women With Early-Stage Breast Cancer Treated With Aromatase Inhibitors. <i>Journal of Oncology Practice</i> , 2017 , 13, e505-e515	3.1	8
102	Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer. <i>European Journal of Cancer Prevention</i> , 2016 , 25, 3-8	2	8
101	Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, e181564	13.4	8
100	The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. <i>European Journal of Cancer</i> , 2019 , 118, 1-9	7.5	8
99	Dynamic classification using case-specific training cohorts outperforms static gene expression signatures in breast cancer. <i>International Journal of Cancer</i> , 2015 , 136, 2091-8	7.5	8
98	Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti-PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer. <i>Clinical Cancer Research</i> , 2021 ,	12.9	8
97	Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status. <i>Journal of Cancer</i> , 2017 , 8, 1045-1052	4.5	7
96	Functional germline variants as potential co-oncogenes. <i>Npj Breast Cancer</i> , 2017 , 3, 46	7.8	7
95	Limitations of pharmacogenomic predictor discovery in Phase II clinical trials. <i>Pharmacogenomics</i> , 2007 , 8, 1443-8	2.6	7
94	Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer. <i>Breast Cancer</i> , 2005 , 12, 73-85	3.4	7

93	Multi-Omics Investigation of Innate Navitoclax Resistance in Triple-Negative Breast Cancer Cells. <i>Cancers</i> , 2020 , 12,	6.6	7
92	Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic. <i>Breast Cancer Research and Treatment</i> , 2021 , 188, 249-258	4.4	7
91	Adjuvant therapy in stage I carcinoma of the breast: the influence of multigene analyses and molecular phenotyping. <i>Cancer</i> , 2012 , 118, 2031-8	6.4	6
90	A 3-gene proliferation score (TOP-FOX-67) can re-classify histological grade-2, ER-positive breast cancers into low- and high-risk prognostic categories. <i>Breast Cancer Research and Treatment</i> , 2013 , 138, 691-8	4.4	6
89	Breast cancer prognostic markers in the post-genomic era. <i>Breast Cancer Research and Treatment</i> , 2011 , 125, 647-50	4.4	6
88	Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: a pooled analysis of four randomized trials. <i>Oncologist</i> , 2010 , 15, 476-83	5.7	6
87	Direct comparison of logistic regression and recursive partitioning to predict chemotherapy response of breast cancer based on clinical pathological variables. <i>Breast Cancer Research and Treatment</i> , 2009 , 117, 325-31	4.4	6
86	Paclitaxel-induced sickle cell crisis. <i>American Journal of Health-System Pharmacy</i> , 2008 , 65, 1333-6	2.2	6
85	A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2- primary breast cancer: CheckMate 7FL. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS604-TPS604	4.2	6
84	Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases. <i>Oncologist</i> , 2021 , 26, 835-844	5.7	6
83	Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx Digital Spatial Profiler. <i>Cancers</i> , 2021 , 13,	6.6	6
82	Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2021 , 7, 1654-1663	13.4	6
81	Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making. <i>Journal of Oncology Practice</i> , 2017 , 13, e1012-e1020	3.1	5
80	RefSeq refinements of UniGene-based gene matching improve the correlation of expression measurements between two microarray platforms. <i>Applied Bioinformatics</i> , 2006 , 5, 89-98		5
79	Abstract PD1-01: Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC) 2020 ,		5
78	Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer 2021 , 9,		5
77	Incorporating Genomics Into the Care of Patients With Advanced Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018 , 38, 56-64	7.1	5
76	Examining the cost-effectiveness of baseline left ventricular function assessment among breast cancer patients undergoing anthracycline-based therapy. <i>Breast Cancer Research and Treatment</i> , 2019 , 176, 261-270	4.4	4

75	Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancers. <i>Breast Cancer Research and Treatment</i> , 2015 , 149, 789-97	4.4	4
74	CCR 20th Anniversary Commentary: Divide and Conquer-Breast Cancer Subtypes and Response to Therapy. <i>Clinical Cancer Research</i> , 2015 , 21, 3575-7	12.9	4
73	Comparison of Residual Risk-Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies. <i>JAMA Oncology</i> , 2018 , 4, e175092	13.4	4
72	A prospective decision-impact study incorporating Breast Cancer Index into extended endocrine therapy decision-making. <i>Breast Cancer Management</i> , 2019 , 8, BMT22	0.7	4
71	Relapse after complete response to anthracycline-based combination chemotherapy in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 1999 , 55, 1-8	4.4	4
70	Treatment scheduling effects on the evolution of drug resistance in heterogeneous cancer cell populations. <i>Npj Breast Cancer</i> , 2021 , 7, 60	7.8	4
69	Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy. <i>Breast Cancer Research</i> , 2021 , 23, 14	8.3	4
68	Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021 , 13,	6.6	4
67	Chemotherapy and the recurrence score--results as expected?. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12, 690-2	19.4	3
66	Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018 , 144, 601-606	4.9	3
65	Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach. <i>Breast Cancer Research and Treatment</i> , 2016 , 155, 223-34	4.4	3
64	Identification of a novel variant in a Hispanic family with early-onset primary open-angle glaucoma with elevated intraocular pressure. <i>Journal of Physical Education and Sports Management</i> , 2019 , 5,	2.8	3
63	Combined analysis of gene expression, DNA copy number, and mutation profiling data to display biological process anomalies in individual breast cancers. <i>Breast Cancer Research and Treatment</i> , 2014 , 144, 561-8	4.4	3
62	Testing violations of the exponential assumption in cancer clinical trials with survival endpoints. <i>Biometrics</i> , 2017 , 73, 687-695	1.8	3
61	Tumor profiling and the incidentalome: patient decisions and risks. <i>Future Oncology</i> , 2015 , 11, 3299-305	3.6	3
60	CECR2 drives breast cancer metastasis by promoting NF- κ B signaling and macrophage-mediated immune suppression.. <i>Science Translational Medicine</i> , 2022 , 14, eabf5473	17.5	3
59	Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)-Positive Breast Cancer. <i>JAMA Network Open</i> , 2020 , 3, e2027074	10.4	3
58	Diverse immune response of DNA damage repair-deficient tumors. <i>Cell Reports Medicine</i> , 2021 , 2, 1002768	6.8	3

57	Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy. <i>Current Treatment Options in Oncology</i> , 2021 , 22, 79	5.4	3
56	Analysis of Pre- and Posttreatment Tissues from the SWOG S0800 Trial Reveals an Effect of Neoadjuvant Chemotherapy on the Breast Cancer Genome. <i>Clinical Cancer Research</i> , 2020 , 26, 1977-1984 ¹²⁻⁹		2
55	Genomic and Immune Profiling of a Patient With Triple-Negative Breast Cancer That Progressed During Neoadjuvant Chemotherapy Plus PD-L1 Blockade. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	2
54	Uncertainty estimation with a finite dataset in the assessment of classification models. <i>Computational Statistics and Data Analysis</i> , 2012 , 56, 1016-1027	1.6	2
53	Control of dataset bias in combined Affymetrix cohorts of triple negative breast cancer. <i>Genomics Data</i> , 2014 , 2, 354-6		2
52	Phase II study of mitoxantrone by 14-day continuous infusion with granulocyte colony-stimulating factor (GCSF) support in patients with metastatic breast cancer and limited prior therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 1999 , 43, 86-91	3.5	2
51	Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a case-control study.. <i>Breast Cancer Research</i> , 2021 , 23, 113	8.3	2
50	Outcomes of adjuvant ACT vs. TC chemotherapy in older women with breast cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1009-1009	2.2	2
49	Reproducibility of homologous recombination deficiency (HRD) scores in biopsies of triple negative breast cancer (TNBC) tumors.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1091-1091	2.2	2
48	Reliability of Whole-Exome Sequencing for Assessing Intratumor Genetic Heterogeneity. <i>SSRN Electronic Journal</i> ,	1	2
47	The Way of the Future: Personalizing Treatment Plans Through Technology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021 , 41, 1-12	7.1	2
46	Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancers. <i>Genome Medicine</i> , 2021 , 13, 70	14.4	2
45	Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor-Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial. <i>Clinical Cancer Research</i> , 2021 , 27, 6115-6123	12.9	2
44	A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer. <i>Cancers</i> , 2021 , 13,	6.6	2
43	Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors.. <i>JCO Precision Oncology</i> , 2022 , 6, e2100181	3.6	2
42	Characterization of DNA variants in the human kinome in breast cancer. <i>Scientific Reports</i> , 2015 , 5, 14736 ^{4.9}		1
41	Computing molecular signatures as optima of a bi-objective function: method and application to prediction in oncogenomics. <i>Cancer Informatics</i> , 2015 , 14, 33-45	2.4	1
40	An adaptive feature selection method for microarray data analysis 2012 ,		1

39	Personalized medicine for breast cancer: moving forward and going back. <i>Personalized Medicine</i> , 2006 , 3, 363-370	2.2	1
38	Long-term survival of de novo stage IV human epidermal growth factor receptor 2 (HER2)-positive breast cancers treated with HER2 targeted therapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1021-1021	2.2	1
37	Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer. <i>Npj Breast Cancer</i> , 2021 , 7, 131	7.8	1
36	Network propagation-based prioritization of long tail genes in 17 cancer types. <i>Genome Biology</i> , 2021 , 22, 287	18.3	1
35	Cancer-specific associations of driver genes with immunotherapy outcome		1
34	Survival outcomes in HER2-positive invasive lobular breast carcinoma.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 612-612	2.2	1
33	Text Messaging to Increase Compliance with Adjuvant Endocrine Therapy in Breast Cancer. <i>Cancer Cell</i> , 2020 , 38, 323-325	24.3	1
32	Clinical Utility of Biomarker Tests in Decisions on Extended Endocrine Therapy. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3942-3943	2.2	1
31	Targeted RNAseq assay incorporating unique molecular identifiers for improved quantification of gene expression signatures and transcribed mutation fraction in fixed tumor samples. <i>BMC Cancer</i> , 2021 , 21, 114	4.8	1
30	TQuest, A Web-Based Platform to Enable Precision Medicine by Linking a Tumor Genetic Defects to Therapeutic Options. <i>JCO Clinical Cancer Informatics</i> , 2018 , 2, 1-13	5.2	1
29	Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 6156-6163	12.9	1
28	The use of microarray technology in the management of breast cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2007 , 5, 193-4, 197	0.6	1
27	Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses. <i>Cancer Research</i> , 2022 , 82, GS1-01-GS1-01	10.1	1
26	Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors.. <i>Npj Breast Cancer</i> , 2022 , 8, 29	7.8	1
25	Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial. <i>Clinical Cancer Research</i> , 2021 , 27, 5607-5618	12.9	0
24	Development of pharmacogenomic predictors for preoperative chemotherapy of breast cancer. <i>Advances in Experimental Medicine and Biology</i> , 2006 , 587, 233-49	3.6	0
23	Abstract OT1-12-04: A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP compared with ddAC-THP in patients with high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11). <i>Cancer Research</i> , 2022 , 82, OT1-12-04-OT1-12-04	10.1	0
22	Evidence of accelerated epigenetic aging of breast tissues in patients with breast cancer is driven by CpGs associated with polycomb-related genes.. <i>Clinical Epigenetics</i> , 2022 , 14, 30	7.7	0

21	Discussion of: "Does lymph node status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer?". <i>American Journal of Surgery</i> , 2017 , 214, 1089-1090	2.7
20	New targets in breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2015 , 8, 86-91	0.3
19	Reply to S. Romero-Cordoba et al.. <i>JCO Precision Oncology</i> , 2020 , 4, 1269-1270	3.6
18	Individualized therapy of breast cancer: are we there yet?. <i>Personalized Medicine</i> , 2008 , 5, 557-559	2.2
17	Data augmentation based on waterfall plots to increase value of response data generated by small single arm Phase II trials. <i>Contemporary Clinical Trials</i> , 2021 , 110, 106589	2.3
16	Association of T- and B-cell receptor repertoires with molecular subtypes and outcome in HER2+ breast cancer: An analysis of the NeoALTTO clinical trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 511-511	2.2
15	A phase Ib multicohort study of MK-3475 in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS3119-TPS3119	2.2
14	An immune-related signature for prediction of risk of late recurrences beyond proliferation and ER-related genes in ER-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 530-530	2.2
13	Pilot study of sorafenib and biweekly capecitabine in patients with advanced breast and gastrointestinal tumors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2561-2561	2.2
12	Application of a dynamic retraining for each patient using case-specific training cohorts to predict survival in breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1065-1065	2.2
11	A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 578-578	2.2
10	Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 538-538	2.2
9	Can routine cavity shave margins (CSM) improve local control in breast cancer? Initial results of the SHAVE trial, a prospective randomized controlled trial of routine CSM vs. standard partial mastectomy (SPM).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1012-1012	2.2
8	A framework to assess the cost effectiveness of predictive biomarkers in oncology: Test Incremental Cost Effectiveness Ratio (TICER).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 6621-6621	2.2
7	Mutation-based treatment recommendations from next generation sequencing data: A comparison of web tools.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e12564-e12564	2.2
6	Contribution of immune system and tumor-related interferon signaling to epirubicin response in triple-negative (TN) breast cancers.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1081-1081	2.2
5	Discovery and disclosure of incidental genetic information obtained through high throughput sequencing.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e17779-e17779	2.2
4	T-DM1 activity in metastatic HER2-positive breast cancers that received prior therapy with trastuzumab and pertuzumab.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 585-585	2.2

- 3 Abstract P1-05-02: Intratumor molecular tumor heterogeneity in low ER-expressing primary breast tumors. *Cancer Research*, **2022**, 82, P1-05-02-P1-05-02 10.1
- 2 Abstract PD5-05: Impact of anti-HER2 therapy alone and in association with weekly paclitaxel on the ovarian reserve of young women with HER2-positive early breast cancer: Biomarker analysis of the NeoALTTO trial. *Cancer Research*, **2022**, 82, PD5-05-PD5-05 10.1
- 1 Abstract P5-17-01: Targeting Acetyl-CoA carboxylase in pre-clinical breast cancer models. *Cancer Research*, **2022**, 82, P5-17-01-P5-17-01 10.1